LALPATHLABDr. Lal Pathlabs

₹3153.7-3.11%

Market Cap

₹26,407.30 Cr

Stock P/E

49.41

ROCE

31.53%

ROE

25.15%

Book Value

₹285.02

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Q1 FY26 revenue grew 11.3% YoY to Rs 670 crore, signaling solid demand and volume momentum.
•
SwasthFit continues to gain traction, contributing 27% of revenue in Q1 FY26.

NEGATIVES

•
West India markets remain underpenetrated vs incumbents, with leadership gaps in Maharashtra and Gujarat.
•
Suburban integration faced execution challenges around collection network and IT stack changes, creating near-term disruption.

Peers Summary

Sector Leader

Dr. Lal Pathlabs Ltd. stands out as a leader in the hospital and healthcare services sector, showcasing strong profitability metrics and a solid growth trajectory compared to its peers. It is relatively undervalued based on its PEG ratio, indicating potential for appreciation. However, some companies like Aster DM Healthcare appear significantly undervalued, albeit with weaker financials.

Key Points

• Dr. Lal Pathlabs exhibits strong growth (10.55% YoY) and profitability (ROE at 21.27%).
• Aster DM Healthcare is the best value pick but shows financial weakness.
• Max Healthcare is overvalued with a high PE ratio (163.58) and low profitability (ROE at 13.47%).

Top Performers

Dr. Lal Pathlabs Ltd.

Strong profitability with ROE at 21.27% and solid revenue growth of 10.55% YoY.

Global Health Ltd.

High revenue growth of 21.56% YoY and decent profitability metrics.

Apollo Hospitals Enterprise Ltd.

Good EPS growth and solid returns on equity.

Explore

Watchlists

Command Palette